AB Biosciences is a biotechnology company located just outside Cambridge, Massachusetts, dedicated to advancing biomedical research through innovative protein engineering.

Our story began in 2007, when founders Yen-Ming Hsu, Hsiu-Ching Chang, and Jeng-Shin Lee — scientists from Biogen, Dana Farber Cancer Institute, and Harvard University — set out to develop target-specific protein therapeutics for autoimmune diseases.

Back then, finding reagents that met the standards required for our internal research was a significant challenge. Instead of compromising, we chose to build in-house protein design and production capabilities, developing mammalian cell–expressed proteins with exceptional biological activity, purity, and consistency. This strategy not only advanced our therapeutic discoveries but also laid the foundation for our reagent store.

In 2016, we began offering these reagents to the biomedical research community worldwide. Today, AB Biosciences supplies more than 120 high-demand protein reagents to leading institutions worldwide — including Stanford University, Roche, Merck, Johnson & Johnson, and the NIH — who rely on them for their reliability and performance.

We are thankful for the confidence the scientific community has shown in us and look forward to continuing to provide researchers everywhere with the tools that drive biomedical progress.